Safety of ceftriaxone sodium at extremes of age.
BACKGROUND
Isolated reports of neonatal and infant deaths associated with ceftriaxone-calcium precipitation in the lungs and kidneys have prompted a recommendation from the US FDA in June 2007 advising that in patients of all ages, calcium-containing solutions should not be administered simultaneously or within 48 h of the last ceftriaxone dose.


OBJECTIVE
To provide a comprehensive review of the literature surrounding the safety of ceftriaxone in the neonatal (< or = 28 days) and geriatric populations (> or = 65 years).


METHODS
Multi-database literature search for original research articles, review articles and case reports pertaining to safety of ceftriaxone in the neonatal and geriatric populations.


CONCLUSIONS
Ceftriaxone should be avoided or significantly minimized in neonates (especially those treated concomitantly with intravenous calcium solutions and those with hyperbilirubinemia), and potentially restricted in the geriatric population treated concomitantly with intravenous calcium.
Monte
Scott V
SV
Diabetes and Cardiovascular Research, CPL Associates, LLC, 3980 Sheridan Drive, Amherst, NY 14226, USA. smonte@cplassociates.com
Prescott
William Allan
WA
Johnson
Kristin K
KK
Kuhman
Lori
L
Paladino
Joseph A
JA